跳至主要内容
临床试验/NCT01981395
NCT01981395已完成1 期

A Double Blind, Randomized, Placebo Controlled, Crossover Study to Investigate the Anti-hyperalgesic Efficacy of a Single Dose of Fenobam on Heat/Capsaicin Induced Cutaneous Hyperalgesia in Adult Healthy Volunteers.

Laura Cavallone1 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2014年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
33
试验地点
1
主要终点
Suppression of the development of cutaneous hyperalgesia and allodynia around the area treated with heat/capsaicin.

研究概览

简要总结

Our goal is to demonstrate that healthy volunteers treated with fenobam will develop a significantly reduced area of cutaneous hyperalgesia compared to volunteers treated with placebo, after exposure to the heat/capsaicin model of cutaneous sensitization. Additionally we are going to assess changes in mood/affect and cognitive function of subjects following administration of fenobam and after cutaneous sensitization compared to baseline.

详细描述

All subjects will receive a topical dose of capsaicin cream 0.1%(Capzasin-HP) to the forearm at the start of the study visit. The order of the 2 treatment regimens indicated below will be randomized and blinded to subjects and researchers.

Treatment Regimen 1: Fenobam [1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine) urea hydrate]: administration of one 150 mg gelatin capsule.

Treatment Regimen 2: Placebo (lactose monohydrate): administration of one 150 mg gelatin capsule.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 18-50 year old
  • Good general health with no remarkable medical conditions (e.g. liver, kidney, heart, or lung failure)
  • BMI between 20-33
  • Willing to comply with study guidelines as outlined in protocol [including: women of childbearing age must be willing to use a double-barrier method (e.g. oral contraception and condom) for contraception during participation in the study]
  • Willing to provide informed consent

排除标准

  • Anatomical malformation of upper extremities
  • Status post recent trauma or chronic lesions on either forearm
  • Medication use (includes vitamin, herbal, dietary and mineral supplements and grapefruit products during or within 14 days prior to study participation; excludes contraceptives)
  • History of allergy or intolerance to capsaicin
  • History of multiple drug allergies
  • History of addiction to drugs or alcohol (prior or present addiction or treatment for addiction)
  • History of chronic pain syndromes
  • Pregnant and nursing females

研究组 & 干预措施

Treatment regimn 1

Experimental

150 mg Fenobam Orally - once

干预措施: Fenobam (Drug)

Treatment Regimen 2

Placebo Comparator

Placebo orally - once

干预措施: Placebo (Drug)

结局指标

主要结局

Suppression of the development of cutaneous hyperalgesia and allodynia around the area treated with heat/capsaicin.

时间窗: During approximately 7 hours of consecutive assessments

size of the area of hyperalgesia and allodynia around the area sensitized by heat/capsaicin as quantified by cutaneous stimulation with foam brush strokes and a von Frey filament requiring 26 g of bending force.

次要结局

  • Evaluation of nociception after drug administration as evaluated by prolonged (1 min) thermal stimulation on normal (untreated) skin.(During approximately 7 hours of consecutive assessments)
  • Assessment of Heat Pain Detection Thresholds (HPDT) in normal and sensitized skin pre and post treatment with fenobam.(During approximately 7 hours of consecutive assessments)
  • Absence of significant side effects(7 days)
  • Assessment of significant change in mood/affect(During approximately 6 hours of consecutive assessments)
  • Assessment of significant change in cognitive function(During approximately 6 hours of consecutive assessments)

研究者

发起方
Laura Cavallone
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Laura Cavallone

Assistant Professor of Anesthesiology

Washington University School of Medicine

研究点 (1)

Loading locations...

相似试验